Last 12,000 KRW
Change Today 0.00 / 0.00%
Volume 105.3K
003220 On Other Exchanges
Symbol
Exchange
Korea SE
As of 2:26 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

daewon pharmaceutical co ltd (003220) Snapshot

Open
11,950
Previous Close
12,000
Day High
12,150
Day Low
11,850
52 Week High
02/5/14 - 13,250
52 Week Low
12/10/13 - 8,743
Market Cap
196.3B
Average Volume 10 Days
117.5K
EPS TTM
761.91
Shares Outstanding
16.4M
EX-Date
12/27/13
P/E TM
15.8x
Dividend
71.43
Dividend Yield
0.60%
Current Stock Chart for DAEWON PHARMACEUTICAL CO LTD (003220)

Related News

No related news articles were found.

daewon pharmaceutical co ltd (003220) Related Businessweek News

No Related Businessweek News Found

daewon pharmaceutical co ltd (003220) Details

Daewon Pharm. Co. Ltd., a pharmaceutical company, engages in the manufacture and sale of medicines in South Korea and internationally. The company primarily offers vitamins and health foods; and medicines for circulatory, respiratory, antibiotic, mental neurological, chemotherapy, and psychoneurosis uses, as well as antipyretic, analgesic, antiinflammatory, gastrointestinal, antimicrobial, cardiovascular, metabolic, neuromuscular, endocrine, and other drugs. Its principal products include Oramin-F soft cap., a multivitamin; Pelubi tablet for pain relief; Aquafol inj. for the anti-exogenous infectious bacteria; Megex-I susp., a medicine supplementing subalimentation of cancer patients; Trigel susp./tab. for the therapy of gastritis and duodenal ulcer; and Metran cap. for use in mammalian physiology. The company was founded in 1958 and is headquartered in Seoul, South Korea.

Founded in 1958

daewon pharmaceutical co ltd (003220) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

daewon pharmaceutical co ltd (003220) Key Developments

Daewon Pharmaceutical Co. Ltd., Annual General Meeting, Mar 14, 2014

Daewon Pharmaceutical Co. Ltd., Annual General Meeting, Mar 14, 2014., at 10:00 Korea Standard Time. Location: hyangnameup Pharmaceutical Corporation , Hwaseong-si. Agenda: To approve the consolidated financial statements for the year ended December 31, 2013; to approve dividend; to consider election of Directors; to consider appointment of Audit Committee; and to approve directors' remuneration limit.

Daewon Pharmaceutical Co. Ltd., Annual General Meeting, Mar 15, 2013

Daewon Pharmaceutical Co. Ltd., Annual General Meeting, Mar 15, 2013., at 10:00 Korea Standard Time. Location: Hyangnam factory Large Conference Room. Agenda: To approve the audit report, sales report, senior external auditor reporting and the consolidated financial statements; to approve statement of appropriation of retained earnings and dividend; to consider the directors' remuneration limit; and to consider the other references useful for making investment decisions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
003220:KS 12,000.00 KRW 0.00

003220 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 003220.
View Industry Companies
 

Industry Analysis

003220

Industry Average

Valuation 003220 Industry Range
Price/Earnings 15.1x
Price/Sales 1.1x
Price/Book 1.5x
Price/Cash Flow 14.8x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAEWON PHARMACEUTICAL CO LTD, please visit www.daewonpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.